Trademark: BIOPERSIST 2375164
Word
BIOPERSIST
ID
2375164
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
26 June 2023
Registration Date
26 June 2023
Renewal Date
26 June 2033
Owner(s)
Service
Goods and Services:
Class 5:
Medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of mental health disorders.
Medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of mental health disorders.
Class 42:
Clinical trials; conducting interventional clinical studies; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research in the fields of clinical trials and post-market trials; scientific research for the development of CRISPR-based platforms and products in the field of genetic engineering.
Clinical trials; conducting interventional clinical studies; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research in the fields of clinical trials and post-market trials; scientific research for the development of CRISPR-based platforms and products in the field of genetic engineering.